Navigation Links
Molecules involved in rheumatoid arthritis angiogenesis identified
Date:5/16/2014

disease.

The investigators found that CCL28, which is over-produced in joints affected by rheumatoid arthritis, attracts the surface-lining cells that carry its receptor.

When the researchers added CCL28 to cells carrying the receptor, the cells organized into blood vessels. But if they chemically blocked the receptor and added CCL28, formation of blood vessels was reduced.

The finding, Shahrara said, provides "strong evidence" that the binding of CCL28 to joint-lining cells carrying its corresponding receptor is a necessary step in angiogenesis.


'/>"/>

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago
Source:Eurekalert

Page: 1 2

Related medicine news :

1. A new method for clicking molecules together
2. Novel small molecules used to visualize prostate cancer
3. Small molecules in the blood might gauge radiation effects after exposure
4. Molecules generated that can halt metastasis of colon cancer
5. Measuring molecules with the naked eye
6. Prions in the brain eliminated by homing molecules
7. Identified 2 new genes involved in the more aggressive prostate cancer
8. AMPK and inflammatory mediators are involved in postoperative cognitive dysfunction
9. Identification of genetic mutations involved in human blood diseases
10. Scientists discover new protein involved in lung cancer
11. Same cell death pathway involved in three forms of blindness, Penn team finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , ... August 27, 2015 , ... According to an ... Conference on Abdominal Wall Hernia Surgery involved many conversations between hernia experts surrounding the ... there, the article notes that many different experts have different ideas about which is ...
(Date:8/27/2015)... ... August 27, 2015 , ... Thriveology Founders, Dr. Carly Letzt Carney and Dr. ... Aging Expo in Denver, Colorado on Saturday, August 29, 2015 at the Marriott DTC, ... outlets as health authorities, and will present a two part seminar entitled, “How to ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, ... second year as sponsor of the “Music With A Mission” benefit concert. For the ... music education programs in the underfunded school districts of Mendon and neighboring town, Quincy, ...
(Date:8/27/2015)... , ... August 27, 2015 , ... The Naderi Center ... be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first ... provides permanent results without surgery. Dr. Kulak is the only Board Certified surgeon ...
(Date:8/27/2015)... ... , ... Healthpointe is proud to welcome Dr. Ted Priebe, O.M.D., CEO of ... practice Chinese Needle Therapy since 1983, Dr. Priebe specializes in the study and treatment ... in Healthpointe’s La Mirada clinic and Garden Grove clinic. , Acupuncture ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 2Health News:Qualified Medical Examiner and Acupuncturist Joins Healthpointe in Los Angeles 3
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
(Date:8/27/2015)... , Aug. 27, 2015 WuXi PharmaTech (Cayman) ... and technology platform company serving the pharmaceutical, ... small-molecule process development and manufacturing subsidiary Shanghai ... first approval from the Japan PMDA for ... a branded commercial drug in July. STA ...
(Date:8/27/2015)... NEWARK, N.J. , Aug. 27, 2015  Symbiomix ... Phase 3 clinical study, the second pivotal trial of ... the treatment of bacterial vaginosis (BV). Earlier this year ... for SYM-1219. Symbiomix expects to finish this second pivotal ... a New Drug Application (NDA) filing with the U.S. ...
(Date:8/27/2015)... 27, 2015 The global ... USD 3.96 billion by 2022, according to a new ... chronic venous disorders such as deep vein thrombosis, leg ... as the key driver.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757) ... are also expected to boost market growth over the ...
Breaking Medicine Technology:WuXi PharmaTech's STA Subsidiary Receives First Approval from Japanese Regulatory Authorities 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 3Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 2Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 3Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 4Compression Therapy Market To Reach $3.96 Billion By 2022: Grand View Research, Inc. 5
... 4, 2011 PRO-DEX, INC. (Nasdaq: PDEX ) ... of the Company,s fiscal 2011 third quarter financial results. ... over the internet on Tuesday, May 10, 2011 at 9:30 ... accessed by visiting the Company,s website at www.pro-dex.com . ...
... 4, 2011 Cardiogenesis Corporation (OTCQB: CGCP), a leading developer ... artery disease, today reported financial results for its first quarter ... quarter of 2011 was $3,053,000, a 6% decrease from prior ... net loss of $433,000, or $0.01 per basic and diluted ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2011 Third Quarter Financial Results Conference Call and Webcast 2Cardiogenesis Reports First Quarter 2011 Results 2Cardiogenesis Reports First Quarter 2011 Results 3Cardiogenesis Reports First Quarter 2011 Results 4Cardiogenesis Reports First Quarter 2011 Results 5Cardiogenesis Reports First Quarter 2011 Results 6
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
Medicine Products: